Ironwood Pharmaceuticals Inc (IRWD) Q4 2025 Earnings Call Highlights: Strong LINZESS Sales and ... [Yahoo! Finance]
Ironwood Pharmaceuticals, Inc. - Class A (IRWD)
Last ironwood pharmaceuticals, inc. - class a earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.ironwoodpharma.com
Company Research
Source: Yahoo! Finance
This article first appeared on GuruFocus LINZESS US Net Sales: $865 million for the full year 2025, with a 13% prescription demand growth in Q4. Adjusted EBITDA: $138 million for the full year 2025. Cash and Cash Equivalents: $250 million at year-end 2025. Total Ironwood Revenue: $296 million for the full year 2025. GAAP Net Income: $24 million for the full year 2025. Operating Expenses Reduction: $61 million reduction year over year. 2026 Guidance for LINZESS US Net Sales: Between $1.125 billion and $1.175 billion, a greater than 30% increase year over year. 2026 Guidance for Adjusted EBITDA: Greater than $300 million. Debt Reduction Plan: Expect to end 2026 with approximately $300 million of debt. Warning! GuruFocus has detected 6 Warning Signs with IRWD. Is IRWD fairly valued? Test your thesis with our free DCF calculator. Release Date: February 25, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript
Show less
Read more
Impact Snapshot
Event Time:
IRWD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IRWD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IRWD alerts
High impacting Ironwood Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
IRWD
News
- Ironwood Pharmaceuticals (IRWD) had its "hold" rating reaffirmed by Jefferies Financial Group Inc..MarketBeat
- Ironwood Pharmaceuticals (IRWD) had its price target raised by Citizens Jmp from $8.00 to $10.00. They now have a "market outperform" rating on the stock.MarketBeat
- Ironwood Pharmaceuticals (IRWD) Reports Q4 Loss, Lags Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 OutlookBusiness Wire
- Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call [Yahoo! Finance]Yahoo! Finance
IRWD
Earnings
- 2/25/26 - Miss
IRWD
Sec Filings
- 2/26/26 - Form 10-K
- 2/25/26 - Form 4
- 2/25/26 - Form 4
- IRWD's page on the SEC website